A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine

BACKGROUND: α‐Synuclein (αSyn) is believed to play a central role in Parkinson's disease (PD) neuropathology and is considered a target for disease modification. UB‐312 is a synthetic αSyn peptide conjugated to a T helper peptide and is expected to induce antibodies specifically against oligome...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Hui Jing, Thijssen, Eva, van Brummelen, Emilie, van der Plas, Johan L., Radanovic, Igor, Moerland, Matthijs, Hsieh, Eric, Groeneveld, Geert Jan, Dodart, Jean‐Cosme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Regular Issue Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545051/
https://www.ncbi.nlm.nih.gov/pubmed/35426173
http://dx.doi.org/10.1002/mds.29016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545051/
https://www.ncbi.nlm.nih.gov/pubmed/35426173
http://dx.doi.org/10.1002/mds.29016

Ejemplares similares